Cullinan Therapeutics, Inc. (CGEM) stock

CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30

$10.19−1.16 (-10.22%)

Close on Nov 12, 2026Market cap $655.77MP/E –Yield –

Cullinan Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Cullinan Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?